Clinical characteristics of children with juvenile dermatomyositis

The childhood arthritis and rheumatology research alliance registry

Angela Byun Robinson, Mark F. Hoeltzel, Dawn M. Wahezi, Mara L. Becker, Elizabeth A. Kessler, Heinrike Schmeling, Ruy Carrasco, Adam M. Huber, Brian M. Feldman, Ann M. Reed

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Objective To investigate aspects of juvenile dermatomyositis (DM), including disease characteristics and treatment, through a national multicenter registry. Methods Subjects meeting the modified Bohan and Peter criteria for definite juvenile DM were analyzed from the cross-sectional Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry between 2010 and 2012 from 55 US pediatric rheumatology centers. Demographics, disease characteristics, diagnostic assessments, and medication exposure data were collected at enrollment. Results A total of 384 subjects met the criteria for analysis. At enrollment, the median Childhood Myositis Assessment Scale score was 51 (interquartile range [IQR] 46-52), the median Childhood Health Assessment Questionnaire score was 0 (IQR 0-0.5), and the median physician and subject global assessment scores were 1 (IQR 0-2) and 1 (IQR 0-3), respectively, out of a maximum of 10. Of the diagnostic assessments, magnetic resonance imaging was more likely than electromyography or muscle biopsy to show abnormalities. A total of 329 subjects had ≥2 diagnostic studies performed, and >34% of these subjects reported ≥1 negative study. Ninety-five percent had been treated with corticosteroids and 92% with methotrexate, suggesting that these medications were almost universally prescribed for juvenile DM in the US. Conclusion In 2 years, the ongoing CARRA Registry has collected clinical data on 384 children with juvenile DM and has the potential to become one of the largest juvenile DM cohorts in the world. More research is needed about prognostic factors in juvenile DM, and differences in therapy based on manifestations of disease need to be explored by practitioners. This registry provides the infrastructure needed to advance clinical and translational research and represents a major step toward improving outcomes of children with juvenile DM.

Original languageEnglish (US)
Pages (from-to)404-410
Number of pages7
JournalArthritis Care and Research
Volume66
Issue number3
DOIs
StatePublished - Mar 2014

Fingerprint

Rheumatology
Arthritis
Registries
Research
Myositis
Translational Medical Research
Electromyography
Juvenile dermatomyositis
Methotrexate
Adrenal Cortex Hormones
Magnetic Resonance Imaging
Demography
Pediatrics
Physicians
Biopsy
Muscles
Health
Therapeutics

ASJC Scopus subject areas

  • Rheumatology

Cite this

Robinson, A. B., Hoeltzel, M. F., Wahezi, D. M., Becker, M. L., Kessler, E. A., Schmeling, H., ... Reed, A. M. (2014). Clinical characteristics of children with juvenile dermatomyositis: The childhood arthritis and rheumatology research alliance registry. Arthritis Care and Research, 66(3), 404-410. https://doi.org/10.1002/acr.22142

Clinical characteristics of children with juvenile dermatomyositis : The childhood arthritis and rheumatology research alliance registry. / Robinson, Angela Byun; Hoeltzel, Mark F.; Wahezi, Dawn M.; Becker, Mara L.; Kessler, Elizabeth A.; Schmeling, Heinrike; Carrasco, Ruy; Huber, Adam M.; Feldman, Brian M.; Reed, Ann M.

In: Arthritis Care and Research, Vol. 66, No. 3, 03.2014, p. 404-410.

Research output: Contribution to journalArticle

Robinson, AB, Hoeltzel, MF, Wahezi, DM, Becker, ML, Kessler, EA, Schmeling, H, Carrasco, R, Huber, AM, Feldman, BM & Reed, AM 2014, 'Clinical characteristics of children with juvenile dermatomyositis: The childhood arthritis and rheumatology research alliance registry', Arthritis Care and Research, vol. 66, no. 3, pp. 404-410. https://doi.org/10.1002/acr.22142
Robinson, Angela Byun ; Hoeltzel, Mark F. ; Wahezi, Dawn M. ; Becker, Mara L. ; Kessler, Elizabeth A. ; Schmeling, Heinrike ; Carrasco, Ruy ; Huber, Adam M. ; Feldman, Brian M. ; Reed, Ann M. / Clinical characteristics of children with juvenile dermatomyositis : The childhood arthritis and rheumatology research alliance registry. In: Arthritis Care and Research. 2014 ; Vol. 66, No. 3. pp. 404-410.
@article{cadbce7f434a4c838d44d667d6fa27eb,
title = "Clinical characteristics of children with juvenile dermatomyositis: The childhood arthritis and rheumatology research alliance registry",
abstract = "Objective To investigate aspects of juvenile dermatomyositis (DM), including disease characteristics and treatment, through a national multicenter registry. Methods Subjects meeting the modified Bohan and Peter criteria for definite juvenile DM were analyzed from the cross-sectional Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry between 2010 and 2012 from 55 US pediatric rheumatology centers. Demographics, disease characteristics, diagnostic assessments, and medication exposure data were collected at enrollment. Results A total of 384 subjects met the criteria for analysis. At enrollment, the median Childhood Myositis Assessment Scale score was 51 (interquartile range [IQR] 46-52), the median Childhood Health Assessment Questionnaire score was 0 (IQR 0-0.5), and the median physician and subject global assessment scores were 1 (IQR 0-2) and 1 (IQR 0-3), respectively, out of a maximum of 10. Of the diagnostic assessments, magnetic resonance imaging was more likely than electromyography or muscle biopsy to show abnormalities. A total of 329 subjects had ≥2 diagnostic studies performed, and >34{\%} of these subjects reported ≥1 negative study. Ninety-five percent had been treated with corticosteroids and 92{\%} with methotrexate, suggesting that these medications were almost universally prescribed for juvenile DM in the US. Conclusion In 2 years, the ongoing CARRA Registry has collected clinical data on 384 children with juvenile DM and has the potential to become one of the largest juvenile DM cohorts in the world. More research is needed about prognostic factors in juvenile DM, and differences in therapy based on manifestations of disease need to be explored by practitioners. This registry provides the infrastructure needed to advance clinical and translational research and represents a major step toward improving outcomes of children with juvenile DM.",
author = "Robinson, {Angela Byun} and Hoeltzel, {Mark F.} and Wahezi, {Dawn M.} and Becker, {Mara L.} and Kessler, {Elizabeth A.} and Heinrike Schmeling and Ruy Carrasco and Huber, {Adam M.} and Feldman, {Brian M.} and Reed, {Ann M.}",
year = "2014",
month = "3",
doi = "10.1002/acr.22142",
language = "English (US)",
volume = "66",
pages = "404--410",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "3",

}

TY - JOUR

T1 - Clinical characteristics of children with juvenile dermatomyositis

T2 - The childhood arthritis and rheumatology research alliance registry

AU - Robinson, Angela Byun

AU - Hoeltzel, Mark F.

AU - Wahezi, Dawn M.

AU - Becker, Mara L.

AU - Kessler, Elizabeth A.

AU - Schmeling, Heinrike

AU - Carrasco, Ruy

AU - Huber, Adam M.

AU - Feldman, Brian M.

AU - Reed, Ann M.

PY - 2014/3

Y1 - 2014/3

N2 - Objective To investigate aspects of juvenile dermatomyositis (DM), including disease characteristics and treatment, through a national multicenter registry. Methods Subjects meeting the modified Bohan and Peter criteria for definite juvenile DM were analyzed from the cross-sectional Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry between 2010 and 2012 from 55 US pediatric rheumatology centers. Demographics, disease characteristics, diagnostic assessments, and medication exposure data were collected at enrollment. Results A total of 384 subjects met the criteria for analysis. At enrollment, the median Childhood Myositis Assessment Scale score was 51 (interquartile range [IQR] 46-52), the median Childhood Health Assessment Questionnaire score was 0 (IQR 0-0.5), and the median physician and subject global assessment scores were 1 (IQR 0-2) and 1 (IQR 0-3), respectively, out of a maximum of 10. Of the diagnostic assessments, magnetic resonance imaging was more likely than electromyography or muscle biopsy to show abnormalities. A total of 329 subjects had ≥2 diagnostic studies performed, and >34% of these subjects reported ≥1 negative study. Ninety-five percent had been treated with corticosteroids and 92% with methotrexate, suggesting that these medications were almost universally prescribed for juvenile DM in the US. Conclusion In 2 years, the ongoing CARRA Registry has collected clinical data on 384 children with juvenile DM and has the potential to become one of the largest juvenile DM cohorts in the world. More research is needed about prognostic factors in juvenile DM, and differences in therapy based on manifestations of disease need to be explored by practitioners. This registry provides the infrastructure needed to advance clinical and translational research and represents a major step toward improving outcomes of children with juvenile DM.

AB - Objective To investigate aspects of juvenile dermatomyositis (DM), including disease characteristics and treatment, through a national multicenter registry. Methods Subjects meeting the modified Bohan and Peter criteria for definite juvenile DM were analyzed from the cross-sectional Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry between 2010 and 2012 from 55 US pediatric rheumatology centers. Demographics, disease characteristics, diagnostic assessments, and medication exposure data were collected at enrollment. Results A total of 384 subjects met the criteria for analysis. At enrollment, the median Childhood Myositis Assessment Scale score was 51 (interquartile range [IQR] 46-52), the median Childhood Health Assessment Questionnaire score was 0 (IQR 0-0.5), and the median physician and subject global assessment scores were 1 (IQR 0-2) and 1 (IQR 0-3), respectively, out of a maximum of 10. Of the diagnostic assessments, magnetic resonance imaging was more likely than electromyography or muscle biopsy to show abnormalities. A total of 329 subjects had ≥2 diagnostic studies performed, and >34% of these subjects reported ≥1 negative study. Ninety-five percent had been treated with corticosteroids and 92% with methotrexate, suggesting that these medications were almost universally prescribed for juvenile DM in the US. Conclusion In 2 years, the ongoing CARRA Registry has collected clinical data on 384 children with juvenile DM and has the potential to become one of the largest juvenile DM cohorts in the world. More research is needed about prognostic factors in juvenile DM, and differences in therapy based on manifestations of disease need to be explored by practitioners. This registry provides the infrastructure needed to advance clinical and translational research and represents a major step toward improving outcomes of children with juvenile DM.

UR - http://www.scopus.com/inward/record.url?scp=84896879731&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896879731&partnerID=8YFLogxK

U2 - 10.1002/acr.22142

DO - 10.1002/acr.22142

M3 - Article

VL - 66

SP - 404

EP - 410

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 3

ER -